Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: August 29th 2022 | Updated: October 13th 2024
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?
Published: February 14th 2022 | Updated: October 13th 2024
Choosing Between Venetoclax or BTK Inhibitors in Frontline CLL
Published: January 25th 2024 | Updated: October 13th 2024
Analysis of Subsequent Therapies Confirms OS Benefit of Darolutamide in mHSPC
Published: January 6th 2023 | Updated: October 13th 2024
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: June 20th 2023 | Updated: October 13th 2024
FDA Grants Approval to Talazoparib Plus Enzalutamide for HRR-Gene Altered mCRPC